Novartis study to compare Femara with AstraZeneca’s Arimidex

Share this article:
Novartis said it has initiated a study to compare its breast cancer drug Femara (letrozole) with AstraZeneca’s best-selling Arimidex (anastrozole), The Wall Street Journal reported. Novartis said the study will look at 4,000 patients around the world. It is the first trial that will compare the two medicines in use after breast cancer surgery. Last year Femara totaled $536 million in sales, compared with around $1.18 billion for Arimidex. AstraZeneca called the study a marketing move. A spokesperson for AstraZeneca told the Journal that the trial would be open-label, meaning that both doctors and patients will know which drugs are being used, unlike clinical studies required to obtain regulatory approval. “There is no scientific rationale for doing this,” the spokesperson said.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.